TheraRadar
Clinical-Stage Companies / Replimune

Replimune

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 12/17/2024

10
Total Trials
2
Phase 3
7
Phase 2
8
Recruiting
95
Score

Pipeline by Phase

Phase 3
2
Phase 2
7
Phase 1
3

Therapeutic Focus

Cancer Metastatic Uveal Melanoma Hepatocellular Carcinoma Biliary Tract Cancer Advanced Melanoma

Clinical Trials (10)

NCT06264180 Phase 3 RECRUITING

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Started: 7/11/2024

NCT06581406 Phase 2 RECRUITING

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Started: 12/17/2024

NCT05733598 Phase 2 RECRUITING

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Started: 8/1/2024

NCT03767348 Phase 2 ACTIVE NOT RECRUITING

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Started: 9/20/2017

NCT05733611 Phase 2 TERMINATED

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Started: 6/29/2023

NCT05743270 Phase 2 WITHDRAWN

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Started: 1/30/2024

NCT04050436 Phase 2 ACTIVE NOT RECRUITING

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Started: 10/8/2019

NCT04349436 Phase 1 ACTIVE NOT RECRUITING

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Started: 5/15/2020

NCT04336241 Phase 1 ACTIVE NOT RECRUITING

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Started: 10/17/2019

NCT04735978 Phase 1 ACTIVE NOT RECRUITING

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Started: 12/29/2020

Drug Candidates

RP2 Ipilimumab Nivolumab Bevacizumab Atezolizumab Durvalumab RP2 Monotherapy Vusolimogene Oderparepvec Nivolumab + Relatlimab Pembrolizumab
Activity Status: Slowing
Last Trial Started: 12/17/2024
Last Trial Ended: 8/18/2025
Trials (12 months): 0
Completed Trials: 0
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.